Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and possesses unique characteristics that make the delivery of drugs to the brain a great challenge. To achieve this purpose, it is necessary to design strategies to allow BBB passage, in order to reach the bra...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/21/11654 |
| _version_ | 1797512468579221504 |
|---|---|
| author | Rúben G. R. Pinheiro Ana Joyce Coutinho Marina Pinheiro Ana Rute Neves |
| author_facet | Rúben G. R. Pinheiro Ana Joyce Coutinho Marina Pinheiro Ana Rute Neves |
| author_sort | Rúben G. R. Pinheiro |
| collection | DOAJ |
| description | The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and possesses unique characteristics that make the delivery of drugs to the brain a great challenge. To achieve this purpose, it is necessary to design strategies to allow BBB passage, in order to reach the brain and target the desired anatomic region. The use of nanomedicine has great potential to overcome this problem, since one can modify nanoparticles with strategic molecules that can interact with the BBB and induce uptake through the brain endothelial cells and consequently reach the brain tissue. This review addresses the potential of nanomedicines to treat neurological diseases by using nanoparticles specially developed to cross the BBB. |
| first_indexed | 2024-03-10T06:02:14Z |
| format | Article |
| id | doaj.art-f8f503332d9e40ada4177774d6bea6d7 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T06:02:14Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-f8f503332d9e40ada4177774d6bea6d72023-11-22T20:55:42ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-10-0122211165410.3390/ijms222111654Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?Rúben G. R. Pinheiro0Ana Joyce Coutinho1Marina Pinheiro2Ana Rute Neves3LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalLAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, PortugalThe blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and possesses unique characteristics that make the delivery of drugs to the brain a great challenge. To achieve this purpose, it is necessary to design strategies to allow BBB passage, in order to reach the brain and target the desired anatomic region. The use of nanomedicine has great potential to overcome this problem, since one can modify nanoparticles with strategic molecules that can interact with the BBB and induce uptake through the brain endothelial cells and consequently reach the brain tissue. This review addresses the potential of nanomedicines to treat neurological diseases by using nanoparticles specially developed to cross the BBB.https://www.mdpi.com/1422-0067/22/21/11654Alzheimer’s diseasedrug deliverydrug targetingneurodegenerative diseasesParkinson’s disease |
| spellingShingle | Rúben G. R. Pinheiro Ana Joyce Coutinho Marina Pinheiro Ana Rute Neves Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? International Journal of Molecular Sciences Alzheimer’s disease drug delivery drug targeting neurodegenerative diseases Parkinson’s disease |
| title | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? |
| title_full | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? |
| title_fullStr | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? |
| title_full_unstemmed | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? |
| title_short | Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? |
| title_sort | nanoparticles for targeted brain drug delivery what do we know |
| topic | Alzheimer’s disease drug delivery drug targeting neurodegenerative diseases Parkinson’s disease |
| url | https://www.mdpi.com/1422-0067/22/21/11654 |
| work_keys_str_mv | AT rubengrpinheiro nanoparticlesfortargetedbraindrugdeliverywhatdoweknow AT anajoycecoutinho nanoparticlesfortargetedbraindrugdeliverywhatdoweknow AT marinapinheiro nanoparticlesfortargetedbraindrugdeliverywhatdoweknow AT anaruteneves nanoparticlesfortargetedbraindrugdeliverywhatdoweknow |